<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846400</url>
  </required_header>
  <id_info>
    <org_study_id>1R61HL151952</org_study_id>
    <nct_id>NCT04846400</nct_id>
  </id_info>
  <brief_title>Pilot Study of a Self-Supporting Nasopharyngeal Airway in Hypotonia</brief_title>
  <acronym>ssNPA</acronym>
  <official_title>Pilot Study of Novel Nasopharyngeal Airway Device for Treating Upper Airway Obstruction in Pediatric Hypotonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with hypotonic upper airway obstruction have a high prevalence of severe obstructive&#xD;
      sleep apnea, which if not treated has significant clinical consequence. Available treatment&#xD;
      approaches, such as surgery and positive airway pressure, show limited efficacy and&#xD;
      adherence. The multidisciplinary team has developed and now proposes to further test a&#xD;
      non-surgical, well-tolerated nasopharyngeal airway device that in initial patients has&#xD;
      resolved even extremely severe obstructive sleep apnea, and improved patient and family&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a critical need for safe and effective treatment options for persistent obstructive&#xD;
      sleep apnea (OSA) in patients with Hypotonic Upper Airway Obstruction (HUAO). HUAO encompass&#xD;
      conditions such as cerebral palsy, hypoxic encephalopathy, syndromic tone anomalies, and&#xD;
      neuromuscular disorders, and typically share a similar pattern of multisite upper airway&#xD;
      collapse. OSA is characterized by recurrent episodes of partial or complete upper airway&#xD;
      obstruction during sleep with associated arousals and/ or oxygen desaturations. Of hypotonic&#xD;
      patients with symptoms of sleep disordered breathing, one quarter have moderate OSA, and more&#xD;
      than half have severe OSA. Thus, not only are patients more likely to have OSA, but it is&#xD;
      likely to be much more severe. Currently available treatment options, ranging from palliative&#xD;
      care to tracheostomy, often fail to fully meet the needs of these patients. The&#xD;
      multidisciplinary team has developed a dramatically effective non-surgical nasopharyngeal&#xD;
      airway stent that has demonstrated good tolerability in hypotonic patients. This initial&#xD;
      phase will test an enhanced version of the device for acceptability and tolerability.&#xD;
      Critically, insertion, adherence, and compliance protocols will be optimized for preparation&#xD;
      of the full trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to tolerate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Score of &gt;=7 on Likert scale 0-10 in at least 60% of participants (higher score is better)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort</measure>
    <time_frame>8 weeks</time_frame>
    <description>Score of &gt;=6 on Likert scale 0-10 in at least 60% of participants (higher score is better)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ease of use</measure>
    <time_frame>8 weeks</time_frame>
    <description>Score of &gt;=5 on Likert scale 0-10 in at least 60% of participants (higher score is better)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Snoring</measure>
    <time_frame>8 weeks</time_frame>
    <description>Less frequent snoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction in Epworth Sleepiness Scale score (0-24; lower score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>8 weeks</time_frame>
    <description>Higher score in parent report of sleep quality on scale 0-10 (higher score is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device design</measure>
    <time_frame>8 weeks</time_frame>
    <description>Device optimization and manufacturing in a clean/sterile manner in 100% of cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insertion protocol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Optimize insertion protocol with ease of insertion &gt;= 5 on Likert scale of 1-10 in 60% of participants (higher score is better)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <condition>Hypotonia</condition>
  <condition>Child, Only</condition>
  <arm_group>
    <arm_group_label>ssNPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>self-supporting nasopharyngeal airway to be used nightly for approximately 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ssNPA</intervention_name>
    <description>The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA</description>
    <arm_group_label>ssNPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hypotonia&#xD;
&#xD;
          -  obstructive sleep apnea on polysomnogram with AHI&gt;=10&#xD;
&#xD;
          -  presence of at least one symptom of OSA (such as snoring 3 or more nights per week,&#xD;
             daytime sleepiness, or hyperactive/inattentive behaviors)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AHI &lt;10&#xD;
&#xD;
          -  any reason why ssNPA may not be suitable&#xD;
&#xD;
          -  Psychiatric, medical, or social factors likely to invalidate assessments, make&#xD;
             adherence with ssNPA highly unlikely or make local follow-up at 8 weeks unfeasible&#xD;
&#xD;
          -  Safe Continuous positive airway pressure therapy (CPAP) use is possible and tolerated&#xD;
&#xD;
          -  Supraglottic airway collapse&#xD;
&#xD;
          -  Distal airway stenosis&#xD;
&#xD;
          -  Tracheobronchomalacia&#xD;
&#xD;
          -  Active COVID 19 infection&#xD;
&#xD;
          -  Need for anticoagulative therapy&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  More than mild elevation of end tidal carbon dioxide (ETCO2) or transcutaneous carbon&#xD;
             dioxide (TCO2) values &gt;60 mmHg for &gt;10% of sleep time&#xD;
&#xD;
          -  Restrictive thoracic disorders&#xD;
&#xD;
          -  Silicone, lidocaine, neosynephrine allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David A Zopf, MD</last_name>
    <phone>734-936-5730</phone>
    <email>davidzop@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise M O'Brien, PhD</last_name>
    <phone>734-647-9064</phone>
    <email>louiseo@med.umich.edu</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>David Zopf</investigator_full_name>
    <investigator_title>Assistant Professor of Otolaryngology-Head and Neck Surgery</investigator_title>
  </responsible_party>
  <keyword>Obstructive sleep apnea</keyword>
  <keyword>Hypotonia</keyword>
  <keyword>Nasal airway</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Muscle Hypotonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>For this initial pilot of 5 participants there are no plans to share data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

